Skip to main content
OTCMKTS:IMUN

Immune Therapeutics Competitors

$7.25
-0.75 (-9.38 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.01
$7.25
50-Day Range
$0.01
$16.00
52-Week Range
$0.01
$0.05
Volume1,818 shs
Average Volume1.62 million shs
Market Capitalization$3.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04

Competitors

Immune Therapeutics (OTCMKTS:IMUN) Vs. NVLNF, NMUS, NTEC, ICOTF, TRLPF, and MCUJF

Should you be buying IMUN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Immune Therapeutics, including Novelion Therapeutics (NVLNF), Nemus Bioscience (NMUS), Intec Pharma (NTEC), iCo Therapeutics (ICOTF), Acerus Pharmaceuticals (TRLPF), and Medicure (MCUJF).

Novelion Therapeutics (OTCMKTS:NVLNF) and Immune Therapeutics (OTCMKTS:IMUN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Institutional & Insider Ownership

48.6% of Novelion Therapeutics shares are owned by institutional investors. Comparatively, 7.7% of Immune Therapeutics shares are owned by institutional investors. 3.6% of Novelion Therapeutics shares are owned by insiders. Comparatively, 11.7% of Immune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Novelion Therapeutics and Immune Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novelion Therapeutics0000N/A
Immune Therapeutics0000N/A

Risk & Volatility

Novelion Therapeutics has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Immune Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Profitability

This table compares Novelion Therapeutics and Immune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novelion TherapeuticsN/AN/AN/A
Immune TherapeuticsN/A-11.54%7,012.86%

Earnings and Valuation

This table compares Novelion Therapeutics and Immune Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novelion Therapeutics$130.43 million0.11$-108,330,000.00N/AN/A
Immune Therapeutics$110,000.0031.77$-3,400,000.00N/AN/A

Immune Therapeutics has lower revenue, but higher earnings than Novelion Therapeutics.

Nemus Bioscience (OTCMKTS:NMUS) and Immune Therapeutics (OTCMKTS:IMUN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Volatility & Risk

Nemus Bioscience has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Immune Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Institutional and Insider Ownership

7.7% of Immune Therapeutics shares are owned by institutional investors. 2.7% of Nemus Bioscience shares are owned by insiders. Comparatively, 11.7% of Immune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Nemus Bioscience and Immune Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nemus Bioscience0000N/A
Immune Therapeutics0000N/A

Profitability

This table compares Nemus Bioscience and Immune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nemus BioscienceN/AN/A-924.42%
Immune TherapeuticsN/A-11.54%7,012.86%

Valuation and Earnings

This table compares Nemus Bioscience and Immune Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nemus BioscienceN/AN/A$-19,190,000.00N/AN/A
Immune Therapeutics$110,000.0031.77$-3,400,000.00N/AN/A

Immune Therapeutics has higher revenue and earnings than Nemus Bioscience.

Summary

Immune Therapeutics beats Nemus Bioscience on 6 of the 7 factors compared between the two stocks.

Intec Pharma (NASDAQ:NTEC) and Immune Therapeutics (OTCMKTS:IMUN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Intec Pharma and Immune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intec PharmaN/A-93.54%-63.98%
Immune TherapeuticsN/A-11.54%7,012.86%

Analyst Recommendations

This is a summary of current recommendations and price targets for Intec Pharma and Immune Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intec Pharma03102.25
Immune Therapeutics0000N/A

Intec Pharma presently has a consensus price target of $13.00, suggesting a potential upside of 286.90%. Given Intec Pharma's higher possible upside, analysts clearly believe Intec Pharma is more favorable than Immune Therapeutics.

Insider and Institutional Ownership

7.7% of Immune Therapeutics shares are owned by institutional investors. 3.3% of Intec Pharma shares are owned by company insiders. Comparatively, 11.7% of Immune Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Intec Pharma and Immune Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intec PharmaN/AN/A$-47,600,000.00($21.80)-0.15
Immune Therapeutics$110,000.0031.77$-3,400,000.00N/AN/A

Immune Therapeutics has higher revenue and earnings than Intec Pharma.

Summary

Immune Therapeutics beats Intec Pharma on 6 of the 9 factors compared between the two stocks.

Immune Therapeutics (OTCMKTS:IMUN) and iCo Therapeutics (OTCMKTS:ICOTF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Immune Therapeutics and iCo Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Therapeutics0000N/A
iCo Therapeutics0000N/A

Earnings and Valuation

This table compares Immune Therapeutics and iCo Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune Therapeutics$110,000.0031.77$-3,400,000.00N/AN/A
iCo TherapeuticsN/AN/A$-1,460,000.00N/AN/A

iCo Therapeutics has lower revenue, but higher earnings than Immune Therapeutics.

Volatility and Risk

Immune Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, iCo Therapeutics has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500.

Institutional & Insider Ownership

7.7% of Immune Therapeutics shares are owned by institutional investors. 11.7% of Immune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Immune Therapeutics and iCo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune TherapeuticsN/A-11.54%7,012.86%
iCo TherapeuticsN/A-472.87%-177.94%

Summary

Immune Therapeutics beats iCo Therapeutics on 6 of the 8 factors compared between the two stocks.

Immune Therapeutics (OTCMKTS:IMUN) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Immune Therapeutics and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune TherapeuticsN/A-11.54%7,012.86%
Acerus Pharmaceuticals-254.66%-346.72%-94.54%

Institutional & Insider Ownership

7.7% of Immune Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Acerus Pharmaceuticals shares are owned by institutional investors. 11.7% of Immune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Immune Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.

Earnings and Valuation

This table compares Immune Therapeutics and Acerus Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune Therapeutics$110,000.0031.77$-3,400,000.00N/AN/A
Acerus Pharmaceuticals$7.38 million1.45$-18,790,000.00N/AN/A

Immune Therapeutics has higher earnings, but lower revenue than Acerus Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Immune Therapeutics and Acerus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Therapeutics0000N/A
Acerus Pharmaceuticals0000N/A

Summary

Immune Therapeutics beats Acerus Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

Immune Therapeutics (OTCMKTS:IMUN) and Medicure (OTCMKTS:MCUJF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Immune Therapeutics and Medicure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune TherapeuticsN/A-11.54%7,012.86%
Medicure-179.92%-63.27%-41.85%

Institutional and Insider Ownership

7.7% of Immune Therapeutics shares are held by institutional investors. 11.7% of Immune Therapeutics shares are held by insiders. Comparatively, 12.9% of Medicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Immune Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Medicure has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Valuation and Earnings

This table compares Immune Therapeutics and Medicure's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune Therapeutics$110,000.0031.77$-3,400,000.00N/AN/A
Medicure$15.20 million0.61$-14,910,000.00N/AN/A

Immune Therapeutics has higher earnings, but lower revenue than Medicure.

Analyst Ratings

This is a summary of recent recommendations for Immune Therapeutics and Medicure, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Therapeutics0000N/A
Medicure0000N/A

Summary

Immune Therapeutics beats Medicure on 7 of the 10 factors compared between the two stocks.


Immune Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NVLNF
Novelion Therapeutics
0.6$0.70-1.2%$13.77 million$130.43 million0.00Gap Up
NMUS
Nemus Bioscience
0.6$0.10-0.0%$13.66 millionN/A0.00High Trading Volume
Gap Up
Intec Pharma logo
NTEC
Intec Pharma
1.4$3.36-2.4%$12.07 millionN/A-0.47Gap Down
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08-1.5%$11.99 millionN/A-3.90Gap Down
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04-24.2%$10.67 million$7.38 million0.00Gap Up
Medicure logo
MCUJF
Medicure
0.6$0.90-10.3%$10.18 million$15.20 million-0.71Gap Down
Williston logo
WHCA
Williston
0.0$0.70-0.0%$9.51 millionN/A0.00
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.11-0.3%$9.33 million$4.08 million-1.24Gap Down
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.16-6.2%$9.02 millionN/A-0.32Gap Up
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.16-6.2%$9.02 millionN/A-0.32Gap Up
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.38-5.3%$8.40 million$2.66 million-12.67News Coverage
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.11-0.0%$8.31 millionN/A0.00
ULUR
ULURU
0.3$0.48-41.5%$8.17 millionN/A0.00Gap Up
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.47-6.4%$8.10 millionN/A-0.63Gap Up
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.05-4.8%$6.90 millionN/A0.00Gap Up
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.31-2.4%$6.40 millionN/A0.00Gap Down
KAYS
Kaya
0.7$0.40-7.0%$6.35 million$1.01 million0.00Gap Down
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.09-7.9%$5.54 millionN/A0.00Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.22-0.0%$4.82 millionN/A-2.43
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.20-0.0%$4.74 million$3.48 million-1.67
BCTXF
BriaCell Therapeutics
0.0$5.95-1.3%$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-0.0%$4.56 millionN/A0.00High Trading Volume
Gap Down
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.04-0.0%$4.00 million$30,000.000.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.04-0.0%$3.89 millionN/A0.00News Coverage
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
RespireRx Pharmaceuticals logo
RSPI
RespireRx Pharmaceuticals
0.5$0.04-7.5%$3.51 millionN/A-0.10Upcoming Earnings
NSPX
Inspyr Therapeutics
0.5$0.01-0.0%$3.33 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-16.7%$3.11 million$20,000.00-1.20Gap Down
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.40-0.0%$3.06 million$9.47 million0.00High Trading Volume
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-0.0%$2.99 millionN/A0.00
INNVD
Innovus Pharmaceuticals
0.6$3.00-59.0%$2.90 million$23.99 million-0.72Gap Up
Amarantus BioScience logo
AMBS
Amarantus BioScience
0.0$0.01-0.0%$2.87 millionN/A0.00
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.07-0.0%$2.86 million$3.65 million0.00Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-0.0%$2.85 million$2 million0.00
IMUCD
ImmunoCellular Therapeutics
0.0$0.51-2.0%$2.14 millionN/A0.00High Trading Volume
Gap Down
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04Upcoming Earnings
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51-0.0%$1.80 millionN/A0.00Gap Down
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03-0.0%$1.63 million$530,000.000.00Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.05-0.0%$1.49 millionN/A0.00
Cardax logo
CDXI
Cardax
0.0$1.75-14.3%$1.41 million$710,000.000.00Gap Down
AOXG
Aoxing Pharmaceutical
0.5$0.02-1.1%$1.35 millionN/A0.00
WWHC
W World
0.8$4.50-0.2%$1.33 millionN/A0.00
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.08-0.0%$1.09 millionN/A0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.02-19.4%$964,000.00$8.73 million0.00Gap Down
AOLS
Aeolus Pharmaceuticals
0.8$0.01-5.8%$836,000.00N/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.14-7.1%$689,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00-11.1%$678,000.00N/A0.00Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.03-0.4%$646,000.00N/A0.00Gap Up
ATRX
Adhera Therapeutics
0.0$0.04-40.5%$640,000.00$250,000.000.00Gap Down
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.